Guilong Zhao

Dr. Guilong Zhao

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2012 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
JHJingli Hou
Jingli Hou
XLXifang Liu
Xifang Liu
JSJie Shen
Jie Shen
GZGuilong Zhao
Guilong Zhao
PWPeng George Wang
Peng George Wang
Introduction: The copper(I)-catalyzed 1,3-dipolar cycloaddition of alkynes and azides to form 1,2,3-triazoles is the most popular reaction in click chemistry. This reaction is also near-perfect, in terms of its robustness, due to the high degree of reliability and complete specificity. Furthermore, this reaction has been used increasingly in drug discovery, because the formed 1,2,3-triazole can act as both a bioisostere and a linker. Areas covered: This review provides an overview of a most important click reaction, 1,3-dipolar cycloadditions of alkynes and azides, in the drug discovery. Expert opinion: Click chemistry is a very powerful tool, in the drug discovery, because it is very efficient in the creation of compound libraries through combinatorial methodology. However, the 1,2,3-triazole ring itself is not a commonly used pharmacophore and has rarely been found in marketed drugs, demonstrating that there are still some limitations during the use of 1,2,3-triazole in the molecules of drug candidates. Hopefully, in the next decade, we will witness the emergence of 1,2,3-triazole-bearing drugs on the market as this click reaction is used more and more widely in the drug discovery.

20 February 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
PWPeng Wei
Peng Wei
LLLingyan Liu
Lingyan Liu
YWYing Wen
Ying Wen
GZGuilong Zhao
Guilong Zhao
FXFengfeng Xue
Fengfeng Xue
TYTao Yi
Tao Yi

29 April 2015 in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
WCWenqing Cai
Wenqing Cai
LJLinlin Jiang
Linlin Jiang
YXYafei Xie
Yafei Xie
YLYuqiang Liu
Yuqiang Liu
WLWei Liu
Wei Liu
GZGuilong Zhao
Guilong Zhao
A brief history of the design of sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors is reviewed. The design of O-glucoside SGLT2 inhibitors by structural modification of phlorizin, a naturally occurring O-glucoside, in the early stage was a process mainly driven by biology with anticipation of improving SGLT2/SGLT1 selectivity and increasing metabolic stability. Discovery of dapagliflozin, a pioneering C-glucoside SGLT2 inhibitor developed by Bristol-Myers Squibb, represents an important milestone in this history. In the second stage, the design of C-glycoside SGLT2 inhibitors by modifications of the aglycone and glucose moiety of dapagliflozin, an original structural template for almost all C-glycoside SGLT2 inhibitors, was mainly driven by synthetic organic chemistry due to the challenge of designing dapagliflozin derivatives that are patentable, biologically active and synthetically accessible. Structure-activity relationships (SAR) of the SGLT2 inhibitors are also discussed.

1 December 2011 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DZDatong Zhang
Datong Zhang
GWGuangtian Wang
Guangtian Wang
GZGuilong Zhao
Guilong Zhao
WXWeiren Xu
Weiren Xu
LHLingyan Huo
Lingyan Huo

1 February 2019 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JWJing-Wei Wu
Jing-Wei Wu
LYLing Yin
Ling Yin
YLYu-Qiang Liu
Yu-Qiang Liu
HZHuan Zhang
Huan Zhang
YXYa-Fei Xie
Ya-Fei Xie
GZGuilong Zhao
Guilong Zhao

27 January 2018 in Molecules
Verified
Journal Article
Open access
PDF file
WCWenqing Cai
Wenqing Cai
JWJingwei Wu
Jingwei Wu
WLWei Liu
Wei Liu
YXYafei Xie
Yafei Xie
YLYuqiang Liu
Yuqiang Liu
GZGuilong Zhao
Guilong Zhao
In order to systematically explore and better understand the structure-activity relationship (SAR) of a diarylmethane backbone in the design of potent uric acid transporter 1 (URAT1) inhibitors, 33 compounds (1a–1x and 1ha–1hi) were designed and synthesized, and their in vitro URAT1 inhibitory activities (IC50) were determined. The three-round systematic SAR exploration led to the discovery of a highly potent novel URAT1 inhibitor, 1h, which was 200- and 8-fold more potent than parent lesinurad and benzbromarone, respectively (IC50 = 0.035 μM against human URAT1 for 1h vs. 7.18 μM and 0.28 μM for lesinurad and benzbromarone, respectively). Compound 1h is the most potent URAT1 inhibitor discovered in our laboratories so far and also comparable to the most potent ones currently under development in clinical trials. The present study demonstrates that the diarylmethane backbone represents a very promising molecular scaffold for the design of potent URAT1 inhibitors.